Background: The most recommended NRTI combinations as first-line antiretroviral treatment for HIV-1 infection in resource-rich settings are tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. Efficacy studies of these combinations also considering pill numbers, dosing frequencies and ethnicities are rare.
Introduction
More than 25 antiretroviral drugs from 6 different drug classes against HIV-1 infection are available today. The standard combination ART (cART) consists of two NRTIs and a potent third agent, e.g. an NNRTI. 1 Recent guidelines recommend tenofovir/emtricitabine or abacavir/lamivudine in combination with either efavirenz or nevirapine, or rilpivirine for individuals with HIV-1-RNA ,100 000 copies/mL as the preferred NRTI backbone for first-line cART including NNRTI. 1, 2 Alternatively, if unavailability or intolerance exists, tenofovir/lamivudine and zidovudine/lamivudine are recommended. 3, 4 These were used in first-line regimens before the availability of tenofovir/emtricitabine and abacavir/ lamivudine as fixed-dose combinations and are still widely used in resource-limited settings.
Studies directly comparing all these four NRTI combinations in large populations are lacking and the relative in vivo efficacy is unclear. Zidovudine/lamivudine showed similar potency as tenofovir/emtricitabine plus efavirenz in a randomized controlled trial, 5 but is no longer a first-line option due to toxicity 6 and twice-daily dosing. 7 Although abacavir/lamivudine and tenofovir/emtricitabine were found to provide comparable antiretroviral efficacy as first-line treatment in a randomized trial, 8 in another clinical trial abacavir/ lamivudine showed inferior virological responses compared with tenofovir/emtricitabine in patients with baseline HIV-RNA levels .100000 copies/mL 9, 10 and abacavir/lamivudine was also associated with more adverse events including lipid abnormalities. 10 Moreover, some randomized trials observed better virological responses for regimens containing tenofovir/emtricitabine than tenofovir/lamivudine, 11 whereas other studies 12, 13 observed equal suppression rates. A recent observational study comparing treatment-naive patients initiating tenofovir/lamivudine or tenofovir/ emtricitabine plus an NNRTI found that tenofovir/lamivudine led to more virological failures (VFs); however, this study did not consider adherence, pill counts or dosing frequency as potential confounders. 14 Comparing NRTI backbones is a complex undertaking because they are formulated differentially: for tenofovir/emtricitabine and abacavir/lamivudine once daily and for zidovudine/lamivudine twice daily fixed-dose combinations exist. Efavirenz can be given in combination with tenofovir/emtricitabine, but is mostly used as a single-tablet regimen including efavirenz/tenofovir/emtricitabine. In addition, lamivudine can be taken once or twice daily in contrast to emtricitabine, which has exclusively the once-daily option. Thus, the daily number of total pills and the maximal dosing frequency can vary substantially among zidovudine, abacavir, emtricitabine, lamivudine and tenofovir in NNRTI-containing regimens. Randomized clinical trials mostly compare just two backbones. They do not necessarily reflect a routine clinical setting because patients are often highly selected due to strict enrolment criteria and men are enrolled over-proportionally in general. However, it is important to examine the treatment efficacy of NRTI backbones with regard to pill burden and dosing frequency, since governments, health insurers and third-party payers may soon start to put pressure on using also non-coformulated ART generics in the future due to considerably lower prices.
The aim of this study was to compare tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine paired with efavirenz or nevirapine as first-line cART regarding virological responses and emergence of NRTI resistance in the representative Swiss HIV Cohort Study (SHCS) and to evaluate the impact of pill burden and dosing frequency on treatment efficacy.
Methods

Selection of patients
Our analysis was based on ART-experienced patients from the SHCS starting treatment up to 8 January 2014. The SHCS, continuously enrolling patients aged 16 or older since 1988, is a prospective and nationwide cohort study including a biobank. The SHCS is representative of the HIV epidemic in Switzerland; it includes at least 53% of all HIV cases ever diagnosed in Switzerland, 72% of all patients receiving ART and 69% of the nationwide registered AIDS cases. 15 Local ethics committees have approved the SHCS for all participating institutions and written informed consent was obtained from all patients. 15, 16 Resistance data are generated from routine clinical testing performed by four laboratories authorized by the Swiss Federal Office of Public Health. All laboratories sequenced the full protease gene and at least codons 28-225 of the reverse transcriptase gene using population-based sequencing with commercial assays (Viroseq Vs.1, PE Biosystems; Viroseq Vs. 2, Abbott AG; VircoTYPE HIV-1 Assay, Virco Lab) or in-house methods. 17 They all participate in the annual quality control evaluation by the Agence Nationale de la Recherche sur le SIDA et les hé patites virales (ANRS) since 2002. All sequences are entered into the SHCS drug-resistance database using SmartGene's Integrated Database Network System (SmartGene, Zug, Switzerland, IDNS version 3.6.3). 18 Additionally, we systematically selected and retrospectively sequenced plasma samples from treatment-naive and treatment-failing patients stored in our biobank, especially for samples obtained before routine genotyping was introduced in 2002.
To compare the efficacy of the different NRTI backbones (tenofovir/ emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine) combined with either efavirenz or nevirapine, we identified HIV-1-infected patients from the SHCS who had initiated their first cART with one of the regimens mentioned above or switched from their first cART to one of these regimens for reasons other than treatment failure. Patients were excluded from the analysis if baseline resistance was identified according to the Stanford database algorithm (mutation penalty score ≥15, Stanford genotypic resistance interpretation algorithm version 7.0: http://sierra2.stanford.edu/sierra/servlet/JSierra).
Furthermore, we assessed tablet usage for pill burden analysis, i.e. whether the three drugs in a regimen were prescribed separately or combined. Patients without complete documentation of this usage information were excluded from pill burden analysis.
Study outcomes
Two primary outcomes were analysed: VF and emergence of NRTI resistance, which was defined as the first detection of any major IAS-USA drug resistance mutation 19 to NRTI following VF. VF was defined as HIV-1 plasma RNA level ≥400 copies/mL after 180 days of continuous treatment. If the subsequent HIV-RNA was ,400 copies/mL, it was considered a viral blip and not a VF. Not all patients experiencing VF had a genotypic resistance test (GRT) performed following VF. Including subjects in the resistance analysis for whom we could not determine whether or not resistance had emerged would potentially be incorrect because they would be included as if they did not have any resistance. Thus, we first compared the characteristics of those with and without GRT following VF within the same regimen group by the Wilcoxon rank-sum test. Variables tested were treatment length, time from treatment initiation to VF, viral load at VF and the consecutive viral load at VF. If there was no evidence for a difference we excluded those with VF, but without GRT, from the resistance analysis.
Statistical methods
We analysed data with univariable and multivariable Cox proportional hazards models to estimate HRs with 95% CIs and used robust standard errors to account for possible intra-patient correlations because a patient could be included twice: (i) first-line cART; and (ii) switched from first-line cART while suppressed. Exposure time started at treatment initiation for every treatment episode. Patients were censored at the time of death, the last visit date or the end of the treatment, whichever came first. Regimens were included categorically in the model.
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Adjustment comprised all variables with univariable significance, which included age (continuous), ethnicity (white/non-white) and treatment initiation year (continuous), and variables decided a priori, including baseline HIV-RNA (log 10 transformed, continuous) and baseline CD4 counts (squareroot transformed, continuous). Baseline CD4 and HIV-RNA data at the initiation of the first cART were retrieved. Missing baseline CD4 (5%) and HIV-RNA (7%) were imputed using multivariable normal regression (an iterative Markov chain Monte Carlo method) and estimated by age, sex, ethnicity, inclusion centre, transmission route and treatment initiation year. In the pill burden analysis, models were adjusted for two more co-variables: pill burden (i.e. the total pill number per day, continuous) and the maximal dosing frequency per day (once/twice daily); both were time-updated variables. Since CD4 counts or pill burden entered categorically did not improve the model fit, we treated them as continuous. Collinearity was tested with variance inflation factors and correlation matrices and none was found.
We performed two sensitivity analyses in which we either restricted NNRTI drugs to efavirenz or our study population to patients on firstline cART.
The analyses were performed using Stata 13.0 SE (StataCorp, TX, USA).
Results
Study population
Since 1996, 9755 patients have been ART-experienced in the SHCS. Among these individuals, 2678 had initiated treatment containing one of the regimens of interest and 1338 had switched from any regimen to one of the regimens of interest. Ninety-nine (7%) patients from the switching group were excluded due to VF or drug resistance identified at switching. This resulted in 3917 treatment episodes from 3398 individuals. Baseline GRT was available for 2477/3398 (73%) patients. Resistance to the prescribed regimen occurred in 77/3398 (2%) patients and these were excluded. In total, our study comprised 3833 treatment episodes from 3321 individuals ( Figure 1 ). Baseline characteristics are summarized in Table 1 . Overall, differences among groups were observed in all characteristics except for ethnicity.
VFs
The following numbers of VFs were observed for the different NRTI backbones (Figure 2a and 
Emergence of NRTI resistance
Next we analysed the relative efficacy of the four NRTI combinations regarding time to the emergence of any NRTI resistance mutation following VF. However, 9 out of 19 (47%) failing regimens with tenofovir/ emtricitabine were not genotyped and the numbers of nongenotyped treatments from failing treatments containing abacavir/ lamivudine, tenofovir/lamivudine and zidovudine/lamivudine, respectively, were 4 out of 9 (44%), 1 out of 11 (9%) and 16 out of 45 (36%). The Wilcoxon rank-sum test did not find an indication of a difference between patients with and without GRT following VF. Because we had no alternative means to determine whether drug resistance had developed in a non-genotyped failure episode, we excluded those without GRT. After exclusion, we detected NRTI resistance in 3 of 1849 (0.2%) tenofovir/emtricitabine-, 1 of 383 (0.3%) abacavir/lamivudine-, 9 of 343 (2.6%) tenofovir/lamivudine-and 17 of 1228 (1.4%) zidovudine/lamivudine-containing treatment episodes ( Figure 2b and Table 1 ).
In the univariable model the HR of abacavir/lamivudine showed no evidence for an effect on the emergence of resistance when compared with tenofovir/emtricitabine [ 
Study population in the pill burden analysis
Since pill number and dosing frequency were essential for the pill burden analysis, patients without full documentation of tablet usage were excluded, resulting in 3089 treatment episodes from 2685 individuals. Given that pill burden and dosing frequency are time-updated variables, we had 4263 observations in total. Median, minimal and maximal numbers of total pills of cART were 2, 1 and 6, respectively. For the tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine regimen groups, the median (IQR) number of total pills was 2 (1-2), 2 (2-3), 4 (4-4) and 3 (3-3), respectively, and the 
Emergence of NRTI resistance in the pill burden analysis
Sensitivity analyses
Sensitivity analyses, in which we restricted NNRTI to efavirenz or our study population to patients on first-line treatment only, robustly showed qualitatively similar results. After adjusting additionally for pill burden and dosing frequency, evidence for effects of regimens both on VF and on the emergence of NRTI resistance was not detected. However, one distinct exception was observed: the abacavir/lamivudine treatment became a stronger predictor of VF in the model restricted to first-line patients [ 
Discussion
In this study, we compared VF rates and emergence of NRTI resistance for the four major NRTI combinations tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/ lamivudine combined with either efavirenz or nevirapine in a realworld clinical setting. Treatment failure rates and frequency of resistance emergence was remarkably low: failure frequencies Assessing efficacy of different nucleos(t)ide backbones 3327 JAC ranged from 1.0% for the tenofovir/emtricitabine to 3.6% for the zidovudine/lamivudine treatment group and the rate of NRTI resistance was even lower, ranging from 0.2% for tenofovir/emtricitabine to 2.6% for tenofovir/lamivudine. In univariable and multivariable analyses we found that abacavir/lamivudine-, tenofovir/ lamivudine-and zidovudine/lamivudine-containing regimens had a .2-fold higher risk of leading to VF than tenofovir/emtricitabinecontaining regimens. Tenofovir/lamivudine was more often associated with emergence of NRTI resistance than tenofovir/emtricitabine. Not taking the pill burden into account, this may suggest superiority of emtricitabine over lamivudine. Among regimens other than tenofovir/emtricitabine, no clear superiority was found. When adjusting for pill burden and dosing frequency, we found that a higher number of pills, but not dosing frequency, was associated with VF and emergence of NRTI resistance. Additionally, a very strong predictor of VF and resistance emergence was non-white ethnicity.
Our results are consistent with a recent meta-analysis showing that lower pill burden was associated with viral suppression. 20 Similarly, patients receiving Atripla (efavirenz/tenofovir/emtricitabine as a single-tablet regimen) had a lower risk of selection for drug resistance compared with patients receiving the same drug components as separate tablets. 21 On the other hand, a large and longterm randomized trial found that twice-daily regimens containing raltegravir performed at least as well as once-daily regimens, 22 demonstrating that, in addition to the convenience of taking a drug regimen, the tolerability of the regimen is also of great importance. In a previous study from the SHCS a higher risk of VF on cART 23 due to inferior self-reported adherence 23, 24 in sub-Saharan African patients was observed. Since white patients infected with non-B subtypes showed improved virological outcomes in the SHCS, 25 differences in adherence, but not between subtypes, could possibly explain the strong effect of ethnicity found in our analyses.
Our study included not only treatment-naive patients initiating their first cART, but also patients switching from their first cART. Several potential problems should be noted in this respect. The first of these is that second-line patients started treatment with fully suppressed HIV-1-RNA. As a result, the risk of developing drug resistance could be smaller than for first-line patients because failure during the time to achieve viral suppression was not possible by definition. However, this was the case for all four regimens and a potential bias is unlikely. Second, for patients Yang et al.
whose NRTI backbone was identical in the first and the second cART (i.e. only the third agent was changed), it was possible that drug resistance had developed as minor variants during the first cART, but was not detected. Thus, second-line treatment might have failed sooner than first-line treatment. However, sensitivity analyses including only first-line patients confirmed that our results were robust, apart from the higher HR of abacavir/ lamivudine-containing regimens on VF. The higher failure rate for abacavir/lamivudine-containing first-line treatments could again point to a higher activity of emtricitabine compared with lamivudine, but to definitely tease out the superiority of emtricitabine, studies with a larger sample size are needed in determining the relative efficacies of these NRTI combinations.
The strength of this study was its representativeness, due to the following facts: (i) patients' HIV-1 viral loads are monitored regularly at 3 month intervals; (ii) viral loads ≥500 copies/mL are genotyped as routine clinical practice; and (iii) retrospective sequencing was performed on available samples for every failed treatment episode even for patients, who were not genotyped, from earlier times. On the other hand, limitations of our study were that failure events were not numerous enough to differentiate between NRTI backbones more precisely. The pill burden analysis showed that HRs of abacavir/lamivudine, tenofovir/ lamivudine and zidovudine/lamivudine compared with tenofovir/emtricitabine for having VF and NRTI resistance were indeed all above 1 but had very wide CIs. On this point, it was difficult to determine whether power issues limited our ability to document evidence of regimen effect from the pill burden analysis. Studies with more individuals are needed to evaluate the relative efficacies of the regimens and to disentangle the effects of pill burden and type of regimen. However, even with our sample size we could observe effects of pill burden and ethnicity. Hence, our data suggested that both ethnicity and pill burden were at least equally important as the substances themselves in affecting treatment efficacy and had a decisive impact on VF and the emergence of NRTI resistance.
In conclusion, although VF and the emergence of resistance were very low in the population studied, tenofovir/emtricitabine appeared to be superior to abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. However, if pill burden and Assessing efficacy of different nucleos(t)ide backbones ethnicity were included in the model these differences became statistically non-significant, illustrating the multifactorial nature of treatment response. Thus, our results indicate a superiority of tenofovir/emtricitabine-containing regimens, but do not allow definitive determination of whether this effect is caused by the lower pill burden or the substances themselves. Finally, our findings are relevant in the light of the upcoming availability of generic drugs. Even when generics are available, the aim of minimizing the pill burden should be maintained. Figure 3 . Kaplan -Meier curves for time to (a) VF and (b) emergence of NRTI resistance in groups with different pill burdens. For the purpose of clear visualization, pill burden was categorized according to the number of pills per day into three groups: 1 -2, 3 -4 and 5 -6. The numbers of failure events are shown in parentheses.
